Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI - Scorecard - MDSpire

Enhancing the Efficacy of Antibody Treatments for New COVID-19 Variants Through Drug Combination Strategies with IDentif.AI

  • By

  • Peter Wang

  • Kui You

  • Zi Wei Chia

  • Lissa Hooi

  • Li Ming Chong

  • De Hoe Chye

  • Angelina Moh

  • Ze Yong Lee

  • Ethan Lim

  • Alrick Zi Xin Kok

  • Stephen Chua

  • Isaiah Zhuang

  • Ella Chang

  • Boon Huan Tan

  • Gladys Gek Yen Tan

  • Shawn Vasoo

  • Conrad E. Z. Chan

  • Edward Kai-Hua Chow

  • Dean Ho

  • June 2, 2026

Share

Clinical Scorecard: Enhancing the Efficacy of Antibody Treatments for New COVID-19 Variants Through Drug Combination Strategies with IDentif.AI

At a Glance

CategoryDetail
Condition
Key MechanismsCombination therapy to enhance efficacy of sotrovimab (STV) against variants.
Target Population
Care Setting

Key Highlights

  • Emerging variants have reduced the efficacy of existing COVID-19 treatments.
  • IDentif.AI identified STV/EIDD-1931 and STV/GS-441524 as effective combinations.
  • These combinations reduced STV's in vitro EC50 by up to 7-fold.
  • No apparent cytotoxicity was observed with the identified combinations.

Guideline-Based Recommendations

Diagnosis

  • Monitor for emerging SARS-CoV-2 variants and their impact on treatment efficacy.

Management

  • Consider combination therapies to enhance the efficacy of existing treatments like STV.

Monitoring & Follow-up

  • Evaluate the effectiveness of drug combinations in clinical trials.

Risks

  • Potential loss of efficacy of previously authorized treatments against new variants.

Patient & Prescribing Data

Patients infected with COVID-19, particularly those with XBB subvariant.

Combination therapies may restore efficacy of previously ineffective drugs.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI

    • by Peter Wang, Kui You, Zi Wei Chia, Lissa Hooi, Li Ming Chong, De Hoe Chye, Angelina Moh, Ze Yong Lee, Ethan Lim, Alrick Zi Xin Kok, Stephen Chua, Isaiah Zhuang, Ella Chang, Boon Huan Tan, Gladys Gek Yen Tan, Shawn Vasoo, Conrad E. Z. Chan, Edward Kai-Hua Chow, Dean Ho

    • June 2, 2026

    Related Content

    AI Tool Finds More Long COVID Cases Than Codes

    Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.

    Pneumonia Etiology and Risk Factors in a Tertiary Hospital During the COVID-19 Era: A Retrospective Analysis (2020–2024)

    Small extracellular vesicles proteome reveals persistent inflammatory and coagulopathic dysregulation in long-COVID